Shire said, as part of its third-quarter results, that it received a subpoena Sept. 23 from the U.S. Department of Health and Human Services and the U.S. Attorney for the Eastern District of Pennsylvania, asking it for documents related to the sales and marketing of Adderall XR, Daytrana and Vyvanse, three drugs for attention deficit hyperactivity disorder, or ADHD.
Friday, October 30, 2009
Shire subpoenaed over ADHD drug marketing
U.K. drug maker Shire said Friday it has been subpoenaed by the U.S. authorities over the marketing of three drugs, as it reported a swing into profit for the third quarter.
Shire said, as part of its third-quarter results, that it received a subpoena Sept. 23 from the U.S. Department of Health and Human Services and the U.S. Attorney for the Eastern District of Pennsylvania, asking it for documents related to the sales and marketing of Adderall XR, Daytrana and Vyvanse, three drugs for attention deficit hyperactivity disorder, or ADHD.
Shire said, as part of its third-quarter results, that it received a subpoena Sept. 23 from the U.S. Department of Health and Human Services and the U.S. Attorney for the Eastern District of Pennsylvania, asking it for documents related to the sales and marketing of Adderall XR, Daytrana and Vyvanse, three drugs for attention deficit hyperactivity disorder, or ADHD.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment